Ibrutinib (Ibr) dose modification for management of early cardiac adverse events in patients with chronic lymphocytic leukemia: Pooled analysis of 7 clinical trials.

B Introduction I : i b Sustained progression-free survival (PFS) has been demonstrated with continuous Ibr-based therapy and with time-limited treatment (tx) with the Ibr + venetoclax (Ven) combination in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). No patient with a dose reduction had recurrence of the same cardiac AE at the same or worse severity, both overall and as a serious AE (vs 22% and 11% in patients without dose reduction, respectively). In total, 17/212 (8%) patients had dose reductions of Ibr (to 280 mg, I n i = 8; to 140 mg, I n i = 9); only 4 patients had a dose reduction specifically following a cardiac AE. [Extracted from the article]